{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-041186","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.712748+00:00","generated_at":"2026-05-24T14:03:55.415940+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Olema reports FY2024 net loss $129.5M; cash $434.1M; palazestrant Phase 3 on track","bullets":["Net loss Q4 $33.6M, FY $129.5M vs. $26.8M and $96.7M in 2023; R&D expense $124.5M FY.","Cash, equivalents & marketable securities $434.1M at Dec 31, 2024, up from $250M private placement.","Phase 3 OPERA-01 monotherapy top-line data expected 2026; OPERA-02 combo trial with Novartis starts 2025.","Phase 1 trial of OP-3136 initiated in Q4 2024; patients currently enrolling.","Updated mPFS data for palazestrant + ribociclib presented at March 2025 TD Cowen; mature data pending."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-041186","json":"https://secwatch.observer/filing/0000950170-25-041186.json","markdown":"https://secwatch.observer/filing/0000950170-25-041186.md","text":"https://secwatch.observer/filing/0000950170-25-041186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017025041186/0000950170-25-041186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017025041186/olma-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:03:55.415940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}